{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:16:53Z","timestamp":1786119413249,"version":"build-2736575974"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1097\/coc.0b013e3181bead47","type":"journal-article","created":{"date-parts":[[2010,3,27]],"date-time":"2010-03-27T05:24:09Z","timestamp":1269667449000},"page":"544-549","source":"Crossref","is-referenced-by-count":6,"title":["Phase II Trial of Dose Dense Docetaxel Followed by FEC100 as Neoadjuvant Chemotherapy in Patients With Operable Breast Cancer"],"prefix":"10.1097","volume":"33","author":[{"given":"William","family":"Jacot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Bibeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Gourgou-Bourgade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Gutowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Emmanuel","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Bleuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Kramar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Romieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210128","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/annonc\/mdl498","article-title":"Estimates of the cancer incidence and mortality in Europe in 2006.","volume":"18","author":"Ferlay","year":"2007","journal-title":"Ann Oncol"},{"key":"R2-2-20210128","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/1097-0142(19940115)73:2<362::AID-CNCR2820730221>3.0.CO;2-L","article-title":"Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast.","volume":"73","author":"Schwartz","year":"1994","journal-title":"Cancer"},{"issue":"17 suppl 10","key":"R3-2-20210128","doi-asserted-by":"crossref","first-page":"x59","DOI":"10.1093\/annonc\/mdl238","article-title":"Meta-analyses of adjuvant therapies for women with early breast cancer: the Early Breast Cancer Trialists' Collaborative Group overview.","author":"Clarke","year":"2006","journal-title":"Ann Oncol"},{"key":"R4-2-20210128","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1200\/JCO.2005.02.6187","article-title":"Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.","volume":"24","author":"Kaufmann","year":"2006","journal-title":"J Clin Oncol"},{"key":"R5-2-20210128","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1200\/JCO.1998.16.8.2672","article-title":"Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.","volume":"16","author":"Fisher","year":"1998","journal-title":"J Clin Oncol"},{"key":"R6-2-20210128","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/jnci\/82.19.1539","article-title":"Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more.","volume":"82","author":"Bonadonna","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"R7-2-20210128","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1200\/JCO.1998.16.1.107","article-title":"Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer.","volume":"16","author":"Ellis","year":"1998","journal-title":"J Clin Oncol"},{"issue":"3 suppl 9","key":"R8-2-20210128","first-page":"1","article-title":"Single-agent docetaxel (Taxotere) in randomized phase III trials.","volume":"26","author":"Burris","year":"1999","journal-title":"Semin Oncol"},{"key":"R9-2-20210128","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/sj.bjc.6600916","article-title":"Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate.","volume":"88","author":"Amat","year":"2003","journal-title":"Br J Cancer"},{"key":"R10-2-20210128","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1200\/JCO.2002.20.6.1456","article-title":"Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel.","volume":"20","author":"Smith","year":"2002","journal-title":"J Clin Oncol"},{"issue":"79 suppl 1","key":"R11-2-20210128","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1023\/A:1024333725148","article-title":"Neoadjuvant docetaxel in locally advanced breast cancer.","author":"Hutcheon","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"R12-2-20210128","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/cncr.20351","article-title":"Reducing the time interval between cycles using standard doses of docetaxel and lenogastrim support: a feasibility study.","volume":"101","author":"Culine","year":"2004","journal-title":"Cancer"},{"key":"R13-2-20210128","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/annonc\/mdh144","article-title":"A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer.","volume":"15","author":"Mitchell","year":"2004","journal-title":"Ann Oncol"},{"key":"R14-2-20210128","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/00001813-200209000-00002","article-title":"Neo-adjuvant therapy with dose-dense docetaxel plus short-term filgrastim rescue for locally advanced breast cancer.","volume":"13","author":"Paciucci","year":"2002","journal-title":"Anticancer Drugs"},{"key":"R15-2-20210128","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00000421-199306000-00006","article-title":"Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate.","volume":"16","author":"Chevallier","year":"1993","journal-title":"Am J Clin Oncol"},{"key":"R16-2-20210128","first-page":"297","article-title":"Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome.","volume":"180","author":"Sataloff","year":"1995","journal-title":"J Am Coll Surg"},{"key":"R17-2-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials.","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"issue":"8 suppl 8","key":"R18-2-20210128","first-page":"25","article-title":"Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.","volume":"11","author":"Nabholtz","year":"1997","journal-title":"Oncology (Williston Park)"},{"key":"R19-2-20210128","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1200\/JCO.1999.17.8.2341","article-title":"Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.","volume":"17","author":"Chan","year":"1999","journal-title":"J Clin Oncol"},{"key":"R20-2-20210128","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/sj.bjc.6600645","article-title":"Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure.","volume":"87","author":"Bonneterre","year":"2002","journal-title":"Br J Cancer"},{"key":"R21-2-20210128","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1093\/annonc\/mdg449","article-title":"Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer.","volume":"14","author":"Ganem","year":"2003","journal-title":"Ann Oncol"},{"key":"R22-2-20210128","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1200\/JCO.2006.07.3916","article-title":"Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.","volume":"24","author":"Roche","year":"2006","journal-title":"J Clin Oncol"},{"key":"R23-2-20210128","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3816\/CBC.2006.n.039","article-title":"Sequential addition of an anthracycline-based regimen to docetaxel as neoadjuvant chemotherapy in patients with operable breast cancer.","volume":"7","author":"Amat","year":"2006","journal-title":"Clin Breast Cancer"},{"key":"R24-2-20210128","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1200\/JCO.1999.17.10.3033","article-title":"Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group.","volume":"17","author":"Miller","year":"1999","journal-title":"J Clin Oncol"},{"key":"R25-2-20210128","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.2001.19.15.3506","article-title":"Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study.","volume":"19","author":"von Minckwitz","year":"2001","journal-title":"J Clin Oncol"},{"key":"R26-2-20210128","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1200\/JCO.2005.05.078","article-title":"Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group.","volume":"23","author":"von Minckwitz","year":"2005","journal-title":"J Clin Oncol"},{"key":"R27-2-20210128","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10549-007-9744-z","article-title":"Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival.","volume":"110","author":"Toi","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"R28-2-20210128","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/annonc\/mdm076","article-title":"A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer.","volume":"18","author":"Natoli","year":"2007","journal-title":"Ann Oncol"},{"key":"R29-2-20210128","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10549-005-3784-z","article-title":"Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II\/III breast cancer.","volume":"93","author":"Ramaswamy","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"R30-2-20210128","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1200\/JCO.2006.09.1777","article-title":"Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14.","volume":"25","author":"Steger","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00000421-201012000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:14:28Z","timestamp":1786040068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000421-201012000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0b013e3181bead47","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}